126
Participants
Start Date
December 31, 2006
Primary Completion Date
August 31, 2010
Study Completion Date
August 31, 2011
Ranibizumab
Ranibizumab for intravitreal injection. .05ml dosing at 30 day intervals and pro re nata (PRN) with dosing criteria.
Laser photocoagulation
Laser photocoagulation in either focal or grid pattern as determined by investigator.
Eye Care Specialists, PC, Kingston
Wilmer Eye Institute at Johns Hopkins University School of Medicine, Baltimore
Duke Eye Center, Durham
Emory University, Atlanta
Midwest Eye Institute, Indianapolis
Black Hills Regional Eye Institute, Rapid City
Illinois Retina Associates Rush University, Chicago
University of Chicago, Chicago
Retinal Consultants of Arizona, Phoenix
University of New Mexico, Albuquerque
Retinal Consultants of Nevada, Las Vegas
University of Southern California, Los Angeles
Retina-Vitreous Associates Medical Group, Beverly Hills
Retina Institute of California, Pasadena
University of California, San Francisco, San Francisco
East Bay Retina Consultants, Oakland
Yale Eye Center, New Haven
Ophthalmic Consultants of Boston, Boston
New England Retina Consultants, PC, West Springfield
Southern New England Retina Associates, Providence
Collaborators (2)
Juvenile Diabetes Research Foundation
OTHER
Genentech, Inc.
INDUSTRY
Johns Hopkins University
OTHER